Mucci Lorelei A, Lagiou Pagona, Hsieh Chung-Cheng, Tamimi Rulla, Hellerstein Susan, Vatten Lars, Adami Hans-Olov, Cnattingius Sven, Trichopoulos Dimitrios
Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA.
BJOG. 2004 Sep;111(9):989-95. doi: 10.1111/j.1471-0528.2004.00232.x.
Because oral contraceptives are so widely used, any health consequences may have substantial public health implications. Whether pregravid oral contraceptives could affect subsequent pregnancies has not been adequately studied. The study objectives were to examine whether pregravid oral contraceptive use affects fetal growth and pregnancy hormone levels.
A prospective study of pregnant women followed through pregnancy.
A major teaching hospital in Boston, USA.
Two hundred and sixty Caucasian pregnant women, with a mean age of 31, and a parity of no more than two. Seventy-nine percent of the women were pregravid oral contraceptive users.
Exposure and covariate data were collected through structured questionnaires. Blood was drawn for hormonal analysis during the 16th and 27th gestational week. Information on pregravid oral contraceptive use included duration and recency of use, and oral contraceptive formulation. Multivariate regression models were used to examine the effect of pregravid oral contraceptive use on birth outcomes and the studied pregnancy hormones.
Birthweight, placental weight, gestational age, pregnancy hormone levels of oestriol and progesterone at 16th and 27th gestational week.
Adjusting for confounders, pregravid oral contraceptive use increased birthweight (mean difference =+207.3 g, 95% CI =+77.6 to +337.1) and placental weight (mean difference =+64.9 g, 95% CI =+13.0 to +116.9) compared with never use. Women with prior oral contraceptive use had higher levels of serum progesterone (P= 0.002) and oestriol (P= 0.12) at the 27th gestational week measurement. The effect on birthweight, placental weight and hormones was stronger among those using oral contraceptives in the previous year and those using a high progestin/high oestrogen potency preparation.
Pregravid oral contraceptive use is positively associated with fetal growth, and this effect may be mediated through oestriol and progesterone.
由于口服避孕药应用广泛,其对健康的任何影响都可能具有重大的公共卫生意义。孕前口服避孕药是否会影响后续妊娠尚未得到充分研究。本研究的目的是探讨孕前口服避孕药的使用是否会影响胎儿生长和妊娠激素水平。
一项对孕妇进行全程跟踪的前瞻性研究。
美国波士顿的一家大型教学医院。
260名白人孕妇,平均年龄31岁,产次不超过2次。79%的女性为孕前口服避孕药使用者。
通过结构化问卷收集暴露因素和协变量数据。在妊娠第16周和第27周采集血液进行激素分析。孕前口服避孕药使用情况的信息包括使用持续时间和近期使用情况以及口服避孕药配方。采用多变量回归模型来研究孕前口服避孕药的使用对出生结局和所研究的妊娠激素的影响。
出生体重、胎盘重量、孕周、妊娠第16周和第27周时雌三醇和孕酮的妊娠激素水平。
在对混杂因素进行校正后,与从未使用过口服避孕药的孕妇相比,孕前使用口服避孕药会增加出生体重(平均差异=+207.3克,95%可信区间=+77.6至+337.1)和胎盘重量(平均差异=+64.9克,95%可信区间=+13.0至+116.9)。在妊娠第27周测量时,既往使用口服避孕药的女性血清孕酮(P=0.002)和雌三醇(P=0.12)水平较高。对于出生体重、胎盘重量和激素的影响,在过去一年使用口服避孕药的女性以及使用高孕激素/高雌激素效力制剂的女性中更为明显。
孕前口服避孕药的使用与胎儿生长呈正相关,这种影响可能通过雌三醇和孕酮介导。